Metabolic effects of GH antagonism in patients with acromegaly.

Authors
Trainer, Peter J
Affiliation
Christie Hospital, Wilmslow Road, Manchester, M20 4BX, UK. peter.trainer@man.ac.uk
Issue Date
2003-08

Metadata
Show full item record
Abstract
Pegvisomant is a growth hormone (GH) receptor antagonist that represents a major advance in the treatment of acromegaly. Initial results with pegvisomant indicate this novel form of therapy to be the most effective treatment available for achieving biochemical disease control as ascertained by circulating IGF-I.
Citation
Metabolic effects of GH antagonism in patients with acromegaly. 2003, 13 Suppl A:S152-6 Growth Horm. IGF Res.
Journal
Growth Hormone & IGF Research
URI
http://hdl.handle.net/10541/78966
DOI
10.1016/S1096-6374(03)00073-X
PubMed ID
12914745
Type
Article
Language
en
ISSN
1096-6374
Collections